secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jazz Pharmaceuticals plc (JAZZ)
CIK:        0001232524
Form:       8-K
Filed at:   2024-07-31T23:59:59+00:00
Accession:  0001232524-24-000065
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jazz Q2 revenue >$1B record; key drugs up 13-22%; guides EPS higher
-------------------------------------------------------------------

- Xywav sales +13%, Epidiolex +22%, Rylaze +6% YoY; oncology revenue +10% YoY.
- Zanidatamab granted Priority Review; PDUFA Nov 29, 2024 for 2L BTC.
- Narrowed 2024 total revenue guidance to $4.0-$4.1B; lowered oncology outlook to $1.10-$1.15B.
- GAAP EPS guidance raised to $6.00-$8.00; non-GAAP EPS to $19.20-$20.30.
- GAAP net income affirmed $385-$530M; non-GAAP adjusted net income $1.275-$1.350B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000065/0001232524-24-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1232524/000123252424000065/jazz-20240731.htm
  HTML page:      https://secwatch.observer/filing/0001232524-24-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer